NCT05169008 - A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular injection

BIOLOGICAL

Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

Nebulized inhalation through the mouth

Trial Locations (2)

Hospital Base de Osorno, Osorno

Hospital Carlos van Buren, Valparaíso